Summary of Study ST002418
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001556. The data can be accessed directly via it's Project DOI: 10.21228/M8K429 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002418 |
Study Title | Serum metabolomics and lipidomics profiling in iliac arteriovenous fistula creation in clinical patients: part 2 |
Study Type | Study of the serum metabolome in patients with end stage kidney disease before and 6-weeks after iliac arteriovenous fistula creation via 1H NMR |
Study Summary | This project is focused on a longitudinal analysis of the small molecules metabolomes in end stage renal disease patients undergoing iliac arteriovenous fistula creation using solution state NMR spectroscopy. It was hypothesized that after 6-weeks of AVF creation, these patients would present with altered serum metabolite features. |
Institute | University of Florida |
Department | Applied Physiology and Kinesiology |
Laboratory | Rm 42 and Rm 43 |
Last Name | Khattri |
First Name | Ram |
Address | 1864 Stadium RD, Gainesville, FL, 32611, USA |
rbk11@ufl.edu | |
Phone | 3307856045 |
Submit Date | 2022-12-22 |
Num Groups | 2 |
Total Subjects | 45 subjects, 2 samples per subject, total of 90 samples |
Num Males | 36 |
Num Females | 9 |
Study Comments | Study of the serum metabolome in patients with end stage kidney disease before and 6-weeks after iliac arteriovenous fistula creation via 1H NMR |
Raw Data Available | Yes |
Raw Data File Type(s) | fid |
Analysis Type Detail | NMR |
Release Date | 2023-12-22 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR002519 |
Treatment Summary: | Metabolomic profile of serum from end stage kidney disease before and 6-week after AVF surgery were evaluated. After 6-week of post op., ESKD patients exhibited difference in few small-molecule environment. A total of 45 ESKD patients were included in this study, with a life expectancy greater than or equal to 9 months (in the period 2012-2015). These patients were evaluated for demographics, comorbidities, hand dominance and prior access history before and 6 weeks post operation. |
Human Fasting: | non-fasted |
Human Endp Clinical Signs: | N/A |